Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50908 |
Name | myelodysplastic syndrome |
Definition | A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myelodysplastic syndrome |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Azacitidine | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Rigosertib Sodium | myelodysplastic syndrome | no benefit | detail... |
ASXL1 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
RUNX1 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
ETV6 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Guadecitabine | myelodysplastic syndrome | not applicable | detail... |
SRSF2 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
U2AF1 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Decitabine | myelodysplastic syndrome | not applicable | detail... |
SETBP1 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
EZH2 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
ZRSR2 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
STAG2 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 E622X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 Y623X | N/A | myelodysplastic syndrome | not applicable | detail... |
SRSF2 P95X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 R625X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 N626X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 H662X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 T663X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 K666X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 K700E | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 I704X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 G740X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 G742X | N/A | myelodysplastic syndrome | not applicable | detail... |
SF3B1 D781X | N/A | myelodysplastic syndrome | not applicable | detail... |
U2AF1 S34X | N/A | myelodysplastic syndrome | not applicable | detail... |
U2AF1 Q157X | N/A | myelodysplastic syndrome | not applicable | detail... |
NRAS G12X | N/A | myelodysplastic syndrome | not applicable | detail... |
NRAS G13X | N/A | myelodysplastic syndrome | not applicable | detail... |
NRAS Q61X | N/A | myelodysplastic syndrome | not applicable | detail... |
IDH2 R140Q | N/A | myelodysplastic syndrome | not applicable | detail... |
IDH2 R172X | N/A | myelodysplastic syndrome | not applicable | detail... |
BCOR mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Cytarabine + Glasdegib | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Cytarabine + Daunorubicin + Glasdegib | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | FF-10501-01 | myelodysplastic syndrome | not applicable | detail... |
NPM1 W288fs | N/A | myelodysplastic syndrome | not applicable | detail... |
FLT3 exon 14 ins | N/A | myelodysplastic syndrome | not applicable | detail... |
FLT3 D835X | N/A | myelodysplastic syndrome | not applicable | detail... |
GATA2 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Danazol | myelodysplastic syndrome | not applicable | detail... |
Unknown unknown | Azacitidine + Hu5F9-G4 | myelodysplastic syndrome | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00801489 | Phase II | Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin | Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias | Recruiting | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Recruiting | USA | 0 |
NCT01211457 | Phase Ib/II | Sapacitabine + Venetoclax Decitabine + Sapacitabine | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes | Unknown status | USA | 0 |
NCT01685411 | Phase 0 | Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam | Busulfan and Cyclophosphamide Followed By ALLO BMT | Recruiting | USA | 0 |
NCT01773395 | Phase II | Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus | GVAX vs. Placebo for MDS/AML After Allo HSCT | Active, not recruiting | USA | 0 |
NCT01804101 | Phase I | CPX-351 | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT01892371 | Phase Ib/II | Azacitidine + Quizartinib Cytarabine + Quizartinib | Quizartinib With Azacitidine or Cytarabine in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT01898793 | Phase Ib/II | Aldesleukin + Cyclophosphamide + Fludarabine ALT-803 + Cyclophosphamide + Fludarabine | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Recruiting | USA | 0 |
NCT01915498 | Phase I | Enasidenib | Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation | Active, not recruiting | USA | 1 |
NCT02019069 | Phase II | CPX-351 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02115295 | Phase II | Cladribine + Cytarabine + Idarubicin Midostaurin | Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) | Recruiting | USA | 0 |
NCT02117219 | Phase I | Azacitidine + Durvalumab | Phase 1 Study to Evaluate MEDI4736 in MDS | Completed | USA | 3 |
NCT02117297 | Phase II | Gemtuzumab ozogamicin | SCT Plus Immune Therapy in Average Risk AML/MDS | Recruiting | USA | 0 |
NCT02193958 | Phase Ib/II | FF-10501-01 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | Completed | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02221310 | Phase II | Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | Recruiting | USA | 0 |
NCT02228525 | Phase II | Selinexor | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | Active, not recruiting | USA | 0 |
NCT02240706 | Phase II | BI 836858 | Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes | Terminated | USA | 1 |
NCT02250937 | Phase II | Cladribine Busulfan Busulfan + Venetoclax Fludarabine | Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT02267863 | Phase I | APTO-253 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Recruiting | USA | 0 |
NCT02269579 | Phase II | CPX-351 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | Withdrawn | USA | 0 |
NCT02273102 | Phase I | Tranylcypromine + Tretinoin | Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) | Completed | USA | 0 |
NCT02281084 | Phase II | Azacitidine Azacitidine + Durvalumab | Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes | Active, not recruiting | USA | 8 |
NCT02367456 | Phase Ib/II | Azacitidine + Glasdegib | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients | Active, not recruiting | USA | CAN | 4 |
NCT02462252 | Phase II | anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone | Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02472145 | Phase III | Decitabine Decitabine + Talacotuzumab | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | Completed | USA | 13 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT02487459 | Phase I | BPX-501 Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02494167 | Phase I | MultiTAA-specific T cells | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | Recruiting | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02508870 | Phase I | Azacitidine Atezolizumab | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Completed | USA | 0 |
NCT02530034 | Phase I | Hu8F4 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Recruiting | USA | 0 |
NCT02530463 | Phase II | Nivolumab Azacitidine Ipilimumab | Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Recruiting | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02553941 | Phase I | Azacitidine + Ibrutinib | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT02556931 | Phase II | Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | Active, not recruiting | USA | 0 |
NCT02562443 | Phase III | Rigosertib Sodium | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) | Active, not recruiting | USA | CAN | 20 |
NCT02564536 | Phase I | Decitabine + Pacritinib | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | Withdrawn | 0 | |
NCT02576301 | Phase Ib/II | Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS | Unknown status | USA | 0 |
NCT02598661 | Phase III | Imetelstat | Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Recruiting | USA | CAN | 15 |
NCT02610777 | Phase II | Azacitidine MLN4924 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Active, not recruiting | USA | CAN | 10 |
NCT02641002 | Phase I | CC-90002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02666950 | Phase II | Adavosertib Cytarabine | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02676323 | Phase Ib/II | Cytarabine + Fludarabine + Leucovorin + Panobinostat | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02677922 | Phase Ib/II | Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib | A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | CAN | 10 |
NCT02683395 | Phase I | PLX51107 | A Study of PLX51107 in Advanced Malignancies | Terminated | USA | 0 |
NCT02684162 | Phase II | Guadecitabine | SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) | Recruiting | USA | 0 |
NCT02719574 | Phase I | Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Recruiting | USA | CAN | 7 |
NCT02721875 | Phase I | Azacitidine Volasertib | Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | Terminated | 1 | |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Recruiting | USA | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |
NCT02728050 | Phase Ib/II | Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone | Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT02743611 | Phase I | Rimiducid BPX-701 | Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT02749708 | Phase Ib/II | IRX5183 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02756572 | Phase I | Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02775903 | Phase II | Azacitidine Azacitidine + Durvalumab | An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | CAN | 10 |
NCT02779777 | Phase II | Tipifarnib | Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | Terminated | USA | 0 |
NCT02786485 | Phase I | Rimiducid BPX-501 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Recruiting | USA | 0 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02795520 | Phase Ib/II | OTS167 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | Recruiting | USA | 0 |
NCT02807558 | Phase II | Azacitidine + Tamibarotene Tamibarotene | A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Active, not recruiting | USA | 1 |
NCT02829840 | Phase Ib/II | Azacitidine + Ponatinib | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT02841540 | Phase I | H3B-8800 | A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 3 |
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Active, not recruiting | USA | 0 |
NCT02848001 | Phase I | CC-90009 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | Recruiting | USA | CAN | 4 |
NCT02890329 | Phase I | Decitabine + Ipilimumab | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT02890758 | Phase I | ALT-803 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Recruiting | USA | 0 |
NCT02907359 | Phase III | Cytarabine Guadecitabine | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Completed | USA | CAN | 12 |
NCT02909972 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02923986 | Phase Ib/II | BP1001 + Dasatinib | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | Withdrawn | USA | 0 |
NCT02935361 | Phase Ib/II | Atezolizumab + Guadecitabine | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | Recruiting | USA | 0 |
NCT02936752 | Phase I | Entinostat + Pembrolizumab | Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure | Active, not recruiting | USA | 0 |
NCT02942290 | Phase II | Azacitidine Azacitidine + Venetoclax | A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | CAN | 5 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Recruiting | USA | 0 |
NCT02966782 | Phase I | Azacitidine + Venetoclax Venetoclax | A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure | Active, not recruiting | USA | 2 |
NCT02979366 | Phase I | MIK665 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | Completed | USA | 3 |
NCT02981914 | Phase 0 | Pembrolizumab | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | Recruiting | USA | 0 |
NCT02989844 | Phase II | ALT-803 | QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT | Recruiting | USA | 0 |
NCT03011034 | Phase II | Talacotuzumab Daratumumab | Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | Active, not recruiting | USA | 5 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Recruiting | USA | 1 |
NCT03042689 | Phase I | Regorafenib | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | Active, not recruiting | USA | 0 |
NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03066648 | Phase I | Decitabine + Spartalizumab Decitabine + Sabatolimab + Spartalizumab Decitabine + Sabatolimab | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | Recruiting | USA | 7 |
NCT03067571 | Phase II | Daratumumab | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03069469 | Phase I | DCC-3014 | Study of DCC-3014 in Patients With Advanced Malignancies | Recruiting | USA | CAN | 5 |
NCT03072043 | Phase Ib/II | APR-246 + Azacitidine | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT03074006 | Phase Ib/II | TEW 7197 | Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS) | Active, not recruiting | USA | 0 |
NCT03075826 | Phase II | Guadecitabine | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | Active, not recruiting | USA | 0 |
NCT03092674 | Phase II | Cytarabine + Decitabine Azacitidine + Midostaurin Decitabine Azacitidine + Nivolumab Azacitidine | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03094637 | Phase II | Azacitidine + Pembrolizumab | Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS) | Recruiting | USA | 0 |
NCT03113643 | Phase I | Azacitidine + Tagraxofusp-erzs + Venetoclax Azacitidine + Tagraxofusp-erzs | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | USA | 0 |
NCT03128034 | Phase Ib/II | Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03151304 | Phase II | Azacitidine + Pracinostat Azacitidine | A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes | Completed | USA | 0 |
NCT03164057 | Phase II | Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03187288 | Phase I | CFI-400945 | A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | CAN | 0 |
NCT03214562 | Phase Ib/II | Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax | Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT03214666 | Phase Ib/II | GTB-3550 TriKE | GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies | Recruiting | USA | 0 |
NCT03238248 | Phase II | Azacitidine + MLN4924 | Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors | Recruiting | USA | 0 |
NCT03248479 | Phase I | Azacitidine + Hu5F9-G4 Hu5F9-G4 | Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies | Recruiting | USA | 1 |
NCT03268954 | Phase III | Azacitidine + MLN4924 Azacitidine | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) | Active, not recruiting | USA | CAN | 18 |
NCT03286114 | Phase I | Pembrolizumab | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Recruiting | USA | 0 |
NCT03306264 | Phase III | Decitabine Decitabine and Cedazuridine | Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML | Recruiting | USA | CAN | 8 |
NCT03326310 | Phase I | Azacitidine + Selumetinib | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia | Recruiting | USA | 0 |
NCT03326921 | Phase I | Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT03358719 | Phase I | Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03359460 | Phase I | Ibrutinib + Lenalidomide | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03383575 | Phase II | Azacitidine + Enasidenib Enasidenib | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03386513 | Phase I | IMGN632 | Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies | Recruiting | USA | 3 |
NCT03393611 | Phase I | anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03397173 | Phase II | Azacitidine + Vitamin C | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | Active, not recruiting | USA | 0 |
NCT03404193 | Phase II | Decitabine + Venetoclax | Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03404726 | Phase I | BAY2402234 | A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies | Recruiting | USA | 1 |
NCT03417154 | Phase II | Cyclophosphamide + Nivolumab | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | Suspended | USA | 0 |
NCT03459859 | Phase I | Cytarabine + MLN4924 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | Recruiting | USA | 0 |
NCT03465540 | Phase I | AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Active, not recruiting | USA | 5 |
NCT03471260 | Phase Ib/II | Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies | Recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Recruiting | USA | 0 |
NCT03515512 | Phase I | Enasidenib | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Recruiting | USA | 0 |
NCT03516591 | Phase I | AMV-564 | A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes | Active, not recruiting | USA | 0 |
NCT03537599 | Phase Ib/II | Daratumumab | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | Recruiting | USA | 0 |
NCT03564821 | Phase I | Ivosidenib | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Recruiting | USA | 0 |
NCT03572764 | Phase I | CPX-351 | CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03573310 | Phase I | JNJ-64619178 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | Recruiting | USA | CAN | 3 |
NCT03594955 | Phase Ib/II | SAR440234 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | Recruiting | USA | 1 |
NCT03603964 | Phase II | Guadecitabine | Guadecitabine Extension Study | Active, not recruiting | USA | CAN | 7 |
NCT03613532 | Phase I | Busulfan + Fludarabine + Venetoclax | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT03614728 | Phase I | Azacitidine + GSK3326595 GSK3326595 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Recruiting | USA | CAN | 0 |
NCT03661307 | Phase Ib/II | Decitabine + Quizartinib + Venetoclax | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03670966 | Phase Ib/II | BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus | 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03672539 | Phase I | Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03699475 | Phase II | BPX-501 + Rimiducid Cyclophosphamide | Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) | Terminated | USA | 0 |
NCT03735446 | Phase I | Cytarabine + Etoposide + Mitoxantrone + Prexasertib | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | Terminated | USA | 0 |
NCT03745716 | Phase III | APR-246 + Azacitidine Azacitidine | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | 1 |
NCT03746041 | Phase I | Abaloparatide + Bevacizumab | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | Recruiting | USA | 0 |
NCT03770429 | Phase I | AZD6738 | AZD6738 for Patients With Progressive MDS or CMML | Recruiting | USA | 0 |
NCT03772925 | Phase I | Belinostat + MLN4924 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03787498 | Phase I | PLX2853 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03807063 | Phase I | Rimiducid BPX-501 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03814005 | Phase I | Azacitidine + MLN4924 | A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment | Recruiting | USA | 1 |
NCT03843528 | Phase I | Azacitidine + Vorinostat | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | Recruiting | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03884829 | Phase I | CYC140 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Recruiting | USA | 0 |
NCT03885947 | Phase I | Cyclophosphamide + Fludarabine + Thiotepa | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Active, not recruiting | USA | 0 |
NCT03886662 | Phase Ib/II | LB-100 | A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | Recruiting | USA | 0 |
NCT03886831 | Phase I | PRT543 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Recruiting | USA | 0 |
NCT03896269 | Phase I | CPX-351 | CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Recruiting | USA | 0 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Recruiting | CAN | 0 |
NCT03915379 | Phase I | JNJ-67571244 | A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Recruiting | USA | 2 |
NCT03927261 | Phase I | PRGN-3006 | PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS | Recruiting | USA | 0 |
NCT03929211 | Phase Ib/II | CPI-613 + Hydroxychloroquine | CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome | Not yet recruiting | USA | 0 |
NCT03931291 | Phase II | APR-246 + Azacitidine | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | Recruiting | USA | 0 |
NCT03932643 | Phase I | ONC201 | ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | Recruiting | USA | 0 |
NCT03940352 | Phase I | HDM201 + Venetoclax HDM201 + Sabatolimab | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Recruiting | USA | 7 |
NCT03946670 | Phase II | Decitabine + Sabatolimab Azacitidine Azacitidine + Sabatolimab Decitabine | A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | Active, not recruiting | USA | CAN | 15 |
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Recruiting | USA | 0 |
NCT03957876 | Phase II | CPX-351 | CPX-351 Therapy for MDS After Hypomethylating Agent Failure | Recruiting | USA | 0 |
NCT03969446 | Phase I | Decitabine + Pembrolizumab | Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | Recruiting | USA | 0 |
NCT03974217 | Phase I | Talazoparib | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | Recruiting | USA | 0 |
NCT04013880 | Phase Ib/II | Decitabine and Cedazuridine + Olutasidenib | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT04021368 | Phase I | SEL120-34A | SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04022785 | Phase I | Azacitidine + PLX51107 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04047641 | Phase II | Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04055844 | Phase II | Decitabine + Ruxolitinib | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | Recruiting | USA | 0 |
NCT04092179 | Phase Ib/II | Enasidenib + Venetoclax | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Recruiting | CAN | 0 |
NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Recruiting | USA | 0 |
NCT04109482 | Phase Ib/II | Cyclophosphamide + Decitabine + Fludarabine + MB-102 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. | Recruiting | USA | 0 |
NCT04128020 | Phase I | Azacitidine + Nivolumab Nivolumab | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | Withdrawn | 0 | |
NCT04128748 | Phase Ib/II | CPX-351 + Quizartinib | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04139434 | Phase I | LP-108 | Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT04140487 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04146038 | Phase II | Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | Recruiting | USA | 0 |
NCT04160052 | Phase Ib/II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04187703 | Phase I | Azacitidine + Decitabine | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | Recruiting | USA | 0 |
NCT04227847 | Phase I | SEA-CD70 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Recruiting | USA | 0 |
NCT04239157 | Phase II | Azacitidine + Canakinumab | Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04243785 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04245397 | Phase I | SX-682 | SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy | Recruiting | USA | 0 |
NCT04264806 | Phase II | ARGX-110 + Azacitidine Azacitidine | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | Not yet recruiting | USA | 11 |
NCT04266301 | Phase III | Azacitidine Azacitidine + Sabatolimab | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) | Recruiting | USA | 26 |
NCT04278768 | Phase I | CA-4948 | An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04284228 | Phase Ib/II | Cyclophosphamide + Fludarabine + NEXI-001 T Cells | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | Recruiting | USA | 0 |
NCT04313881 | Phase III | Azacitidine Azacitidine + Hu5F9-G4 | Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE) | Recruiting | USA | 1 |
NCT04361058 | Phase I | Nivolumab | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | Recruiting | USA | 0 |
NCT04401748 | Phase III | Azacitidine + Venetoclax Azacitidine | Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) | Recruiting | USA | CAN | 21 |
NCT04417517 | Phase Ib/II | ALX148 + Azacitidine | A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) | Recruiting | USA | 0 |
NCT04487106 | Phase II | Azacitidine + Trametinib + Venetoclax | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04493138 | Phase Ib/II | Azacitidine + Quizartinib | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | Recruiting | USA | 0 |
NCT04493164 | Phase II | CPX-351 + Ivosidenib Ivosidenib | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Not yet recruiting | USA | 0 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT04550442 | Phase Ib/II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04582864 | Phase II | Flotetuzumab | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | Not yet recruiting | USA | 0 |
NCT04655755 | Phase Ib/II | Decitabine and Cedazuridine + Venetoclax | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Not yet recruiting | USA | 0 |
NCT04708054 | Phase II | Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax | Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome | Not yet recruiting | USA | 0 |
NCT04734990 | Phase Ib/II | Azacitidine + Seclidemstat | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Not yet recruiting | USA | 0 |